A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Solid Malignancies or Lymphomas

Interventions

BIOLOGICAL

IBI363

a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.

Trial Locations (4)

RECRUITING

RECRUITING

Westmead Hospital, Sydney

RECRUITING

Sydney Southwest Private Hospital, Sydney

RECRUITING

Cancer Care Wollongong, Sydney

All Listed Sponsors

collaborator

Fortvita Biologics (USA)Inc.

INDUSTRY

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY